Drugs in Development
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ACE1702,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: ACE1702
Highest Development Status: Phase I Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Available
Deal Size: Not Available Upfront Cash: Not Available
Deal Type: Not Available November 02, 2020
Details:
Poster titled A potent and off-the-shelf oNK cell therapy product targets HER2+ cancer cells and resists suppressive tumor microenvironment will be presented at the at The Society for Immunotherapy of Cancer 35th Anniversary Annual Meeting.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ACE1702,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: ACE1702
Highest Development Status: Phase I Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 18, 2020
Details:
The study will evaluate the safety and tolerability, pharmacodynamics, and preliminary efficacy of ACE1702 in patients with advanced or metastatic HER2-expressing solid tumors not amenable to surgery or other therapeutic options.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ACE1702
Therapeutic Area: Oncology Product Name: ACE1702
Highest Development Status: Phase I Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2020
Details:
The data was presented in a digital poster session at the 2020 AACR Annual Meeting II. ACE1702 is Acepodia’s lead off-the-shelf cell therapy candidate and recently received investigational new drug clearance from the U.S. FDA to be evaluated in Phase 1 clinical trials.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ACE1702
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 08, 2020
Details:
Preclinical data for early stage ACC- and CAR-oNK cell therapy candidates demonstrate promise in models of solid tumors and hematological malignancies .
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
